title: Update on prognostic markers for endometrial cancer.
abstract: Endometrial cancer is the most common gynecologic cancer in the USA and the second most common worldwide after cervical cancer. While common symptomatology of endometrial cancer leads to early diagnosis and favorable 5-year survival in most cases, there is a subset of cancers that have a poorer prognosis. The clinical and pathologic prognostic factors for endometrial cancer are well known and instrumental in determining the need for adjuvant therapy. Recently, research has been focused on the identification of molecular changes leading to different histologic subtypes to improve classification of endometrial cancer. The identification of novel mutations and molecular profiles should enhance our ability to personalize adjuvant treatment with genome-guided targeted therapy.
authors: Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Washington University  School of Medicine in St Louis, MO, USA.
authors: Pratibha S
authors: PS
authors: Binder
authors: David G
authors: DG
authors: Mutch
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D014943:Global Health; D006801:Humans; D058990:Molecular Targeted Therapy; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors; D014481:United States; D016387:Women's Health
chemical_list: D014408:Biomarkers, Tumor
keywords: biologic markers; endometrial cancer; prognosis; targeted therapy